MA34083B1 - Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques - Google Patents

Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques

Info

Publication number
MA34083B1
MA34083B1 MA35240A MA35240A MA34083B1 MA 34083 B1 MA34083 B1 MA 34083B1 MA 35240 A MA35240 A MA 35240A MA 35240 A MA35240 A MA 35240A MA 34083 B1 MA34083 B1 MA 34083B1
Authority
MA
Morocco
Prior art keywords
spiro
pharmaceutical compositions
therapeutic agents
topical administration
oxindole compound
Prior art date
Application number
MA35240A
Other languages
Arabic (ar)
English (en)
Inventor
Conrad Stewart Winters
Meidong Yang
Haigang Chen
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43981337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34083(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA34083B1 publication Critical patent/MA34083B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques destinées à une administration topique à un mammifère, les compositions pharmaceutiques comprenant un composé spiro-oxindole, sous la forme d'un énantiomère, d'un racémate ou d'un mélange non racémique, ou un sel pharmaceutiquement acceptable de celui-ci. Ces compositions pharmaceutiques sont utiles pour le traitement et/ou la prévention de maladies ou conditions médiées par les canaux sodiques.
MA35240A 2010-02-26 2011-02-25 Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques MA34083B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30875910P 2010-02-26 2010-02-26
PCT/US2011/026359 WO2011106729A2 (fr) 2010-02-26 2011-02-25 Compositions pharmaceutiques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques.

Publications (1)

Publication Number Publication Date
MA34083B1 true MA34083B1 (fr) 2013-03-05

Family

ID=43981337

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35240A MA34083B1 (fr) 2010-02-26 2011-02-25 Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques

Country Status (23)

Country Link
US (2) US9504671B2 (fr)
EP (2) EP2538919B1 (fr)
JP (2) JP2013521232A (fr)
KR (1) KR20120131162A (fr)
CN (2) CN105726531A (fr)
AU (2) AU2011220396B2 (fr)
BR (1) BR112012021086A2 (fr)
CA (1) CA2788440A1 (fr)
CL (1) CL2012002126A1 (fr)
CO (1) CO6571900A2 (fr)
EC (1) ECSP12012171A (fr)
HR (1) HRP20120740A2 (fr)
IL (1) IL221646A (fr)
MA (1) MA34083B1 (fr)
MX (1) MX343215B (fr)
MY (1) MY165117A (fr)
NZ (1) NZ601667A (fr)
PE (1) PE20121699A1 (fr)
PH (1) PH12012501564A1 (fr)
RU (2) RU2016128400A (fr)
SG (1) SG183126A1 (fr)
TN (1) TN2012000421A1 (fr)
WO (1) WO2011106729A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
WO2008060789A2 (fr) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Utilisation de composés de spiro-oxindole comme agents thérapeutiques
WO2010045251A2 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2010306768B2 (en) 2009-10-14 2016-08-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011072141A1 (fr) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions et procédés pour le traitement de la dégénérescence maculaire
US10065950B2 (en) 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
AU2013246485A1 (en) 2012-04-12 2014-10-16 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
GB201312295D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
WO2015120151A1 (fr) 2014-02-05 2015-08-13 Teva Pharmaceuticals International Gmbh Formulation topique d'un composé de spiro-oxindole destiné au traitement d'une douleur associée à l'ostéoarthrite d'une articulation
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2016133967A2 (fr) * 2015-02-18 2016-08-25 Parion Sciences, Inc. Bloqueurs de canaux sodiques pour le traitement de troubles de la peau
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
BR112018012327A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem
WO2017218920A1 (fr) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Synthèse asymétrique de funapide
AU2017283651B2 (en) 2016-06-16 2021-03-25 Xenon Pharmaceuticals, Inc. Solid state forms of spiro-oxindole compounds
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
MX2020009813A (es) * 2018-03-29 2020-11-11 Lumosa Therapeutics Co Ltd Composiciones y metodos para tratar el prurito.
JP2019206497A (ja) * 2018-05-30 2019-12-05 小林製薬株式会社 外用医薬組成物
US20200038392A1 (en) * 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
EP3833660A4 (fr) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. Composés polymorphes et leurs utilisations
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP4027979A4 (fr) * 2019-09-09 2023-10-04 Pacira Therapeutics, Inc. Gels thermodurcissables à libération prolongée comprenant des bloqueurs de canaux sodiques et leurs procédés de fabrication
CA3175856A1 (fr) 2020-05-13 2021-11-18 Todd Brady Formulations pharmaceutiques et leurs utilisations

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US614969A (en) 1898-11-29 murphy
US3189617A (en) 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
DE1956237A1 (de) 1969-11-08 1971-05-13 Basf Ag Spiro-pyrrolizidon-oxindole
DE2113343A1 (de) 1971-03-19 1972-09-21 Thiemann Chem Pharm Fab Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CH577461A5 (fr) 1975-08-13 1976-07-15 Robins Co Inc A H
US4670566A (en) 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4440785A (en) 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4569942A (en) 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
US4690943A (en) 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721721A (en) 1984-12-18 1988-01-26 Rorer Pharmaceutical Corporation 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses
DE3608088C2 (de) 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
WO1993012786A1 (fr) 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
JP2716986B2 (ja) 1987-07-17 1998-02-18 シエーリング アクチエンゲゼルシヤフト ９‐ハロゲン‐（ｚ）‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用
US5182289A (en) 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
ES2110965T3 (es) 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5484778C1 (en) 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
WO1992009577A1 (fr) 1990-11-22 1992-06-11 Janssen Pharmaceutica N.V. Derives d'acide isonicotinique et composes spiroapparentes a action herbicide
US5116854A (en) 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
SK283413B6 (sk) 1992-08-06 2003-07-01 Warner-Lambert Company 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze
US5278162A (en) 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5776936A (en) 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en) 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
AT400950B (de) 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
AU2310895A (en) 1994-04-07 1995-10-30 Cemaf Novel spiro{indole-pyrrolidine} derivatives as melatoninergic agonists, method for preparing same and use thereofas a drug
US5618819A (en) 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
FR2722195B1 (fr) 1994-07-07 1996-08-23 Adir Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0799226B1 (fr) 1994-12-22 2001-02-07 Smithkline Beecham Plc Composes spiro tetracycliques, procedes de preparation et utilisation comme antagonistes du recepteur 5ht1d
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
CA2235686C (fr) 1995-10-24 2007-06-26 Sanofi Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
HUP9600855A3 (en) 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0989856B1 (fr) 1997-01-20 2010-05-12 IMMODAL PHARMAKA GESELLSCHAFT m.b.H. Procede et substances pour liberer un facteur de croissance issu des cellules endotheliales, facteur de croissance libere selon ce procede, et son utilisation
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
KR20000070903A (ko) 1997-02-10 2000-11-25 오노 야꾸힝 고교 가부시키가이샤 11,15-ｏ-디알킬프로스타글란딘 ｅ 유도체, 이것의 제조 방법 및 이것을 유효 성분으로 함유하는 약제
US6416780B1 (en) 1997-05-07 2002-07-09 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
WO1999033794A1 (fr) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. DERIVES φ-CYCLOALKYLES DE LA PROSTAGLANDINE E¿2?
JP4087938B2 (ja) 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
SK285908B6 (sk) 1998-04-01 2007-10-04 Nortran Pharmaceuticals Inc. Aminocyklohexyléterová zlúčenina, kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny pri výrobe liečiva a pri liečbe
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
WO2000006556A1 (fr) 1998-07-27 2000-02-10 Abbott Laboratories Antiproliferants a base d'oxazolines substituees
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
ES2258459T3 (es) 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
WO2001006984A2 (fr) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Petites particules utiles pour le traitement de maladies inflammatoires
CZ2002203A3 (cs) 1999-07-21 2002-08-14 Astrazeneca Ab Spirooxindolové deriváty
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CA2394229C (fr) 1999-11-26 2010-04-13 Mcgill University Loci pour epilepsie generalisee idiopathique, leurs mutations, et methode utilisant ceux-ci pour evaluer, diagnostiquer, pronostiquer ou traiter l'epilepsie
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
US20020045566A1 (en) 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
IL154928A0 (en) 2000-11-10 2003-10-31 Lilly Co Eli 3-substituted oxindole beta 3 agonists
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
EP1444224B1 (fr) 2001-08-14 2006-05-03 Eli Lilly And Company Agonistes de beta-3 a base d'oxyndole 3-substitue
WO2003037890A2 (fr) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
ATE297925T1 (de) 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
JP2005519921A (ja) 2002-01-28 2005-07-07 ファイザー株式会社 Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003078394A1 (fr) 2002-03-15 2003-09-25 Eli Lilly And Company Derives de dihydroindol-2-one modulant le recepteur nucleaire de l'hormone steroide
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
IL165395A0 (en) 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
BR0312092A (pt) 2002-06-25 2005-03-22 Wyeth Corp Uso de derivados de tio-oxindol no tratamento de distúrbios da pele
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
KR20120102571A (ko) 2003-02-24 2012-09-18 미쓰비시 타나베 파마 코퍼레이션 테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도
EP1626722A1 (fr) 2003-05-16 2006-02-22 Pfizer Products Inc. Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
BRPI0410419A (pt) 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
CN1780626A (zh) 2003-05-16 2006-05-31 辉瑞产品公司 双相性精神障碍和相关症状的治疗
JP2007502856A (ja) 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
KR20060037409A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피페라진 유도체 및 그의 치료제로서의 용도
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (fr) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
WO2005035498A1 (fr) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire
EP1557166A1 (fr) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Derives d'alpha-aminoamides pour le traitement des désordres de l'appareil urinaire inférieur
US7507760B2 (en) 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
WO2005092858A2 (fr) 2004-03-29 2005-10-06 Pfizer Japan Inc. Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
US20080280873A1 (en) 2004-03-29 2008-11-13 Jun Liang Biaryl Substituted Pyrazinones as Sodium Channel Blockers
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
WO2005099689A1 (fr) 2004-04-01 2005-10-27 Case Western Reserve University Apport topique de phtalocyanines
CA2562399A1 (fr) 2004-04-08 2005-10-20 Topotarget A/S Composes de diphenyl ox-indol-2-on et leur utilisation dans le traitement du cancer
WO2005104711A2 (fr) 2004-04-27 2005-11-10 Wyeth Purification de modulateurs de recepteur de progesterone
MXPA06012660A (es) 2004-05-05 2007-03-23 Unibioscreen Sa Derivados de naftalimida para el tratamiento de cancer.
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2005111024A1 (fr) 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine destines au traitement de croissance cellulaire anormale
EP1758882A4 (fr) 2004-06-24 2008-01-23 Incyte Corp Composes amido et utilisation de ceux-ci comme agents pharmaceutiques
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP4677323B2 (ja) 2004-11-01 2011-04-27 キヤノン株式会社 画像処理装置及び画像処理方法
BRPI0518281A2 (pt) 2004-11-18 2008-11-18 Incyte Corp inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
DE102005007694A1 (de) 2005-02-18 2006-09-21 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
EA019566B1 (ru) 2005-02-22 2014-04-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AU2006242542A1 (en) 2005-04-29 2006-11-09 Wyeth Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
CA2620034C (fr) 2005-09-01 2013-10-01 F. Hoffmann-La Roche Ag Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
US7888345B2 (en) 2006-06-09 2011-02-15 Merck Sharp & Dohme Corp. Benzaepinones as sodium channel blockers
JP2010522690A (ja) 2006-10-12 2010-07-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド 三環式スピロオキシインドール誘導体および治療薬としてのその使用
WO2008046083A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés oxindole comme agents thérapeutiques
TW200833698A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046087A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
RU2009117605A (ru) 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) ПРОИЗВОДНЫЕ СПИРО-(ФУРО[3,2-c]ПИРИДИН-3-3'-ИНДОЛ)-2'(1'H)-ОНА И РОДСТВЕННЫЕ ИМ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ НАТРИЕВЫМИ КАНАЛАМИ ЗАБОЛЕВАНИЙ, ТАКИХ КАК БОЛЬ
WO2008060789A2 (fr) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Utilisation de composés de spiro-oxindole comme agents thérapeutiques
WO2008046084A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
WO2008046082A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés hétérocycliques comme agents thérapeutiques
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2008117050A1 (fr) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazines pyrazolyl-amino substituées et utilisation de ces composés pour le traitement du cancer
NZ582013A (en) 2007-05-29 2012-03-30 Intrexon Corp Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
CA2741024A1 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Composes spiro-oxindole et leur utilisation comme agents therapeutiques
WO2010045251A2 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
WO2010053998A1 (fr) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Dérivés d'indole spiro-condensés utilisables en tant qu'inhibiteurs des canaux sodiques
WO2010078307A1 (fr) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Dérivés de spiro-oxindole en tant que bloqueurs de canaux sodiques
WO2010132352A2 (fr) 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Composés spiro et leur utilisation en tant qu'agents thérapeutiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2010306768B2 (en) 2009-10-14 2016-08-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
AU2013246485A1 (en) 2012-04-12 2014-10-16 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Also Published As

Publication number Publication date
CN102946859A (zh) 2013-02-27
US20130143941A1 (en) 2013-06-06
ECSP12012171A (es) 2012-10-30
HRP20120740A2 (hr) 2012-12-31
PH12012501564A1 (en) 2019-07-17
JP2013521232A (ja) 2013-06-10
PE20121699A1 (es) 2012-12-22
CO6571900A2 (es) 2012-11-30
TN2012000421A1 (en) 2014-01-30
EP2538919B1 (fr) 2017-07-12
HK1182619A1 (zh) 2013-12-06
US20170095449A1 (en) 2017-04-06
AU2011220396B2 (en) 2016-10-13
SG183126A1 (en) 2012-09-27
WO2011106729A3 (fr) 2012-11-15
AU2011220396A1 (en) 2012-09-13
KR20120131162A (ko) 2012-12-04
CL2012002126A1 (es) 2012-09-28
RU2016128400A (ru) 2018-12-06
CN105726531A (zh) 2016-07-06
AU2017200159A1 (en) 2017-02-02
IL221646A (en) 2017-05-29
MY165117A (en) 2018-02-28
WO2011106729A2 (fr) 2011-09-01
EP2538919A2 (fr) 2013-01-02
JP2016135806A (ja) 2016-07-28
MX2012009838A (es) 2012-09-21
CA2788440A1 (fr) 2011-09-01
RU2012140955A (ru) 2014-04-10
RU2596488C2 (ru) 2016-09-10
MX343215B (es) 2016-10-27
US9504671B2 (en) 2016-11-29
CN102946859B (zh) 2016-03-02
EP3266444A1 (fr) 2018-01-10
NZ601667A (en) 2014-10-31
BR112012021086A2 (pt) 2016-05-17

Similar Documents

Publication Publication Date Title
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu&#39;agents thérapeutiques
MA35576B1 (fr) Nouveaux composés
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
TN2014000449A1 (en) Complement pathway modulators and uses thereof
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
NZ708593A (en) Novel pyrazole derivative
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
GB2511685A (en) Muscarinic m1 receptor agonists
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
MX392150B (es) Moduladores de receptores canabinoides.
MX2010009462A (es) Derivados de indazol.
EA201591177A1 (ru) Трициклические соединения для ингибирования канала cftr
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
BR112015014433A2 (pt) compostos tricíclicos
EA201391524A1 (ru) Производные гликозида и их применение
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
EA201490573A1 (ru) Соединение бензотиазолона
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu&#39;antagonistes des récepteurs des orexines
SA521431274B1 (ar) مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.